TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03066544
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
Study: NCT01053221
Drug: Mycophenolic Acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
Study: NCT01053221
Drug: Standard of Care: CNI and MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
Study: NCT00841659
Drug: Paxil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Film-Coated Tablet
Study: NCT06001463
Drug: CSMed Dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
Study: NCT02385708
Drug: 2% Chlorohexidine Gluconate Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
Study: NCT02385708
Drug: 2% Chlorohexidine Gluconate Chin to Toe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
Study: NCT04171115
Drug: G03-52-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: G03-52-01 administered intramuscularly
Study: NCT04171115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intramuscularly
Study: NCT04464889
Drug: MDG1021 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
Study: NCT04464889
Drug: MDG1021 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
Study: NCT04464889
Drug: MDG1021 dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
Study: NCT04464889
Drug: MDG1021 optimal dose
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 patients to receive the selected optimal dose
Study: NCT00538109
Drug: Glivec®/Gleevec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT00438984
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02442687
Drug: JKB-121: 5 mg twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02442687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00420927
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
Study: NCT00002744
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002744
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002744
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002744
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002744
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00382460
Drug: PRAVASTATIN SODIUM
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01947205
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02419508
Drug: Brinz/brim vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo for masking purposes
Study: NCT02280278
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02447848
Drug: sufentanil sublingual 30 mcg tablet
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001698
Drug: Ketorolac Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00834873
Drug: COREG® 25 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 25 mg
Study: NCT00354835
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01769898
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 0.1 Q12H
Study: NCT01769898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for theophylline 0.1 Q12H
Study: NCT01968551
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study: NCT01968551
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tablet administered orally once daily
Study: NCT01968551
Drug: Baseline DRV- containing ARV regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take their baseline DRV- containing ARV regimen as prescribed.
Study: NCT03982537
Drug: N-Acetyl-L-Cysteine dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
Study: NCT02055547
Drug: MK-8521 150μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
Study: NCT03938389
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
Study: NCT02055547
Drug: MK-8521 50/72μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
Study: NCT02055547
Drug: MK-8521 72/125μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
Study: NCT02055547
Drug: MK-8521 100/150μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
Study: NCT02055547
Drug: MK-8521 125/150μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
Study: NCT02055547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
Study: NCT04260373
Drug: [14C]SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
Study: NCT00573313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
Study: NCT04143607
Drug: ASK120067
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT04143607
Drug: Placebo ASK120067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT03031795
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03031795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT04015024
Drug: SKLB1028 150mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg oral administration twice a day
Study: NCT04015024
Drug: SKLB1028 200mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg oral administration twice a day
Study: NCT04015024
Drug: SKLB1028 300mg qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg oral administration once a day
Study: NCT03232021
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule administered 1 hour prior to the surgical operation
Study: NCT03856164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
Study: NCT01220622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo 30mg tid for 6 months
Study: NCT01600963
Drug: Arm A Double-blind Phase: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
Study: NCT01600963
Drug: Arm B Double-blind Phase: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
Study: NCT01600963
Drug: Treatment Failure During Double-blind Phase: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
Study: NCT01600963
Drug: Treatment Failure During Follow-up Phase: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
Study: NCT00087529
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00518986
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01301430
Drug: H-1PV
Normalized name: Synovex H
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
Study: NCT02660502
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of a single dose of Humalog® at the dose of 0.2 U/kg
Study: NCT01972230
Drug: Diprivan + Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06626971
Drug: ARA290
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg subcutaneous injections of ARA290 over an 84 day period
Study: NCT01430442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant placebo-matching capsules
Study: NCT03718143
Drug: AZD1775 only
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 days 1-5 \& 8-12
Study: NCT00699517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion followed by administration of cisplatin
Study: NCT00767377
Drug: EOF5
Normalized name: Ethinyl Estradiol and Norgestimate
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
Study: NCT00494897
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00494897
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00919113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The identical buffer used in Uracyst for the same administration
Study: NCT04552990
Drug: Jet injection of ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
Study: NCT00543205
Drug: Genasense® (G3139, oblimersen sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genasense 7 mg/kg/day for 5 days
Study: NCT00494897
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00142883
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill compared to pregabalin
Study: NCT04309968
Drug: Drug: SYHA1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SYHA1801 administered orally
Study: NCT02764515
Drug: Kunxian Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
Study: NCT02764515
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
Study: NCT01285713
Drug: 5% Dextrose (D5) in Normal Saline (NS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
Study: NCT00911053
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
Study: NCT01283503
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02832960
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study: NCT03636061
Drug: OC-01 (varenicline) nasal spray
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline) nasal spray
Study: NCT03636061
Drug: Placebo (vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03217331
Drug: CRD-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg CRD-102 capsules administered twice daily orally for 14 days.
Study: NCT01602692
Drug: Tumescent solution with dilute lidocaine and epinephrine
Normalized name: epinephrine / lidocaine Injectable Solution [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
Study: NCT01602692
Drug: Tumescent Solution with dilute epinephrine
Normalized name: Sensorcaine with Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tumescent Solution containing dilute epinephrine (1:1,000,000) only
Study: NCT01343498
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
Study: NCT03771677
Drug: Nucleotide Analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: such as Entecavir,entecavir 0.5mg per day
Study: NCT02549716
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
Study: NCT00353262
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 po bid (cycles 1, 2 and 3)
Study: NCT02549716
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
Study: NCT00688753
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03591471
Drug: Sulfotanshinone Sodium Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
Study: NCT03591471
Drug: Chinese herbs based on syndrome differentiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome.
Study: NCT02549716
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
Study: NCT02549716
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
Study: NCT00003414
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01275222
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
Study: NCT03591471
Drug: Low Molecular Weight Heparin Calcium Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
Study: NCT03591471
Drug: Chinese medicine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
Study: NCT03092154
Drug: Lipid-lowering agents (Artovastatin)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artovastatin 20 mg /day, orally, 12 consecutive weeks.
Study: NCT01533389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
Study: NCT00995826
Drug: CS-8958
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled CS-8958
Study: NCT04152382
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04152382
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04152382
Drug: LY3509754
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04152382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00634894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule by mouth daily x 12 weeks
Study: NCT01055171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg; Single Dose.
Study: NCT01685281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be similar in appearance (color and size) to the investigational product
Study: NCT00940225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03182088
Drug: norepinephrine infusion (0.025 mcg/Kg/min)
Normalized name: mepivacaine 0.025 MG/ML / norepinephrine 30 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
Study: NCT03182088
Drug: norepinephrine infusion (0.050 mcg/Kg/min)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
Study: NCT03182088
Drug: norepinephrine infusion (0.075 mcg/Kg/min)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
Study: NCT01114425
Drug: Truvada®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02562053
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive oral fluoxetine 20 mg daily.
Study: NCT02028221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)